MAPT and Alzheimer disease: It also prevented tau hyperphosphorylation and suppressed microglial inflammation by upregulating the soluble receptors for the advanced glycation end products (sRAGE) and downregulating TNF-α, IL-1β, and IL-6, ultimately leading to ameliorating results in AD-like cognitive deficits.